[1]刘瑜瑜,赵辽辽,思雅芳.狼疮性肾炎患者血清SMAD2，TRAF3水平表达及与预后的相关性研究[J].现代检验医学杂志,2025,40(05):136-140,144.[doi:10.3969/j.issn.1671-7414.2025.05.025]
　LIU Yuyu,ZHAO Liaoliao,SI Yafang.Expression of Serum SMAD2 and TRAF3 Levels in Patients with Lupus Nephritis and Their Correlation with Prognosis[J].Journal of Modern Laboratory Medicine,2025,40(05):136-140,144.[doi:10.3969/j.issn.1671-7414.2025.05.025]
点击复制

狼疮性肾炎患者血清SMAD2，TRAF3水平表达及与预后的相关性研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年05期
页码:
136-140,144
栏目:
论著
出版日期:
2025-09-15

文章信息/Info

Title:
Expression of Serum SMAD2 and TRAF3 Levels in Patients with Lupus Nephritis and Their Correlation with Prognosis
文章编号:
1671-7414（2025）05-136-06
作者:
刘瑜瑜，赵辽辽，思雅芳
西安交通大学第一附属医院榆林医院肾病内科，陕西榆林 719000
Author(s):
LIU Yuyu，ZHAO Liaoliao，SI Yafang
Department of Nephrology, Yulin Hospital, the First Affiliated Hospital of Xi’an Jiaotong University, Shaanxi Yulin 719000, China
关键词:
狼疮性肾炎; 小母亲抗肢瘫同系物2; 肿瘤坏死因子受体相关因子3
分类号:
R593.242；R392.11
DOI:
10.3969/j.issn.1671-7414.2025.05.025
文献标志码:
A
摘要:
目的探讨狼疮性肾炎（LN）患者血清小母亲抗肢瘫同系物2（SMAD2）、肿瘤坏死因子受体相关因子3（TRAF3）水平表达及与预后的相关性。方法选取2021年1月～2023年3月西安交通大学第一附属医院榆林医院收治的LN患者150例（LN组）和单纯系统性红斑狼疮患者80例（非LN组），随访1年将LN患者分为不良预后组（n=61）和良好预后组（n=89）。采用酶联免疫吸附法（ELISA）检测血清SMAD2和TRAF3水平。采用多因素非条件Logistic回归分析LN患者不良预后的影响因素；绘制受试者工作特征曲线（ROC）评价血清SMAD2，TRAF3水平对LN患者预后的预测能效。结果与非LN组比较，LN组血清SMAD2（5.34±1.16ng/mlvs2.98±1.11ng/ml）和TRAF3（91.23±12.58ng/Lvs74.28±11.91ng/L）水平升高，差异具有统计学意义（t=14.917，9.852，均P＜0.05）。随访1年，150例LN患者不良预后发生率为40.67%（61/150）。与良好预后组比较，不良预后组血清SMAD2（6.03±1.02ng/mlvs4.86±1.00ng/ml）和TRAF3（98.65±10.49ng/Lvs86.15±11.35ng/L）水平升高，差异具有统计学意义（t=7.015，6.830，均P＜0.05）。LN患者不良预后的独立危险因素为慢性肾脏病分期增加、SMAD2升高、TRAF3升高，独立保护因素为估算肾小球滤过率（eGFR）升高（Waldχ2=9.633～16.666，均P＜0.05）。血清SMAD2，TRAF3水平预测LN患者不良预后的曲线下面积（AUC）大于血清SMAD2，TRAF3水平单独预测，差异具有统计学意义（Z=3.658，3.606，均P＜0.05）。结论LN患者血清SMAD2，TRAF3水平升高，与不良预后密切相关，血清SMAD2，TRAF3水平联合对LN患者不良预后有较高的预测效能。
Abstract:
Objective To investigate the expression of serum levels of small mothers against decapentaplegic homolog 2 (SMAD2) and tumor necrosis factor receptor-related associated factor 3 (TRAF3) in patients with lupus nephritis (LN) and their correlation with prognosis. Methods A total of 150 patients with LN (LN group) and 80 patients with systemic lupus erythema-tosus(SLE) without nephritis (non-LN group) treated at Yulin Hospital, the First Affiliated Hospital of Xi’an Jiaotong University from January 2021 to March 2023 were selected. Patients with LN were followed up for 1 year and divided into the poor progno-sis group (n=61) and the good prognosis group (n=89). Serum levels of SMAD2 and TRAF3 were measured using enzyme-linked immunosorbent assay(ELISA). Multivariate unconditional logistic regression was used to identify factors affecting poor progno-sis in LN patients, and receiver operating characteristic (ROC) curves were constructed to evaluate the predictive efficacy of se-rum SMAD2 and TRAF3 levels for LN prognosis. Results Compared with the non-LN group, serum SMAD2 (5.34±1.16ng/ml vs 2.98±1.11ng/ml) and TRAF3 (91.23±12.58ng/L vs 74.38±11.91ng/L) levels were significantly elevated in the LN group, and the differences were statistically significant (t=14.917, 9.852, all P＜0.05). During the 1-year follow-up, the incidence of poor prognosis among the 150 LN patients was 40.67% (61/150). Compared with the good prognosis group, serum SMAD2 (6.03±1.02ng/ml vs 4.86±1.00ng/ml) and TRAF3 (98.65±10.49ng/L vs 86.15±11.35ng/L) levels were significantly higher in the poor prognosis group, and the differences were statistically significant (t=7.015, 6.830, all P＜0.05). The independent risk factors for poor prognosis in LN patients were advanced chronic kidney disease stage, elevated SMAD2 and elevated TRAF3 , while the independent protective factor was increased estimated glomerular filtration rate(eGFR)(Wald χ2=9.633～16.666, all P＜0.05). The area under the curve(AUC) of predicting poor prognosis in LN patients by serum SMAD2 and TRAF3 levels was larger than that predicted by serum SMAD2 alone and TRAF3 levels alone, and the differences were statistically significant(Z=3.658, 3.606, all P＜0.05). Conclusion Elevated serum SMAD2 and TRAF3 levels in LN patients are closely associated with poor prognosis. The combination of serum SMAD2 and TRAF3 levels has high predictive efficacy for poor prognosis in LN patients.

参考文献/References:

[1] 沈南,赵毅,段利华,等.系统性红斑狼疮诊疗规范[J].中华内科杂志,2023,62(7):775-784. SHEN N, ZHAO Y, DUAN L H, et al. Recommen-dations for diagnosis and treatment of systemic lupus erythematosus[J]. Chinese Journal of Internal Medi-cine,2023,62(7):775-784.
[2] 冉涛,潘锋,王永红,等.系统性红斑狼疮患者血清sMI-CA, sMICB 水平与自身抗体表达及疾病活动度的相关性研究[J].现代检验医学杂志,2024,39(4):100-104,149. RAN T, PAN F, WANG Y H, et al. Correlation among serum sMICA, sMICB levels, autoantibody expression and disease activity in patients with systemic lupus erythematosus[J]. Journal of Modern Laboratory Medi-cine,2024,39(4):100-104,149.
[3] 张辉,杨念生,鲁静,等.狼疮肾炎诊疗规范[J].中华内科杂志,2021,60(9):784-790. ZHANG H, YANG N S, LU J, et al. Recommendations for the diagnosis and management of lupus nephri-tis in China[J]. Chinese Journal of Internal Medi-cine,2021,60(9):784-790.
[4] 米雪,杨小娟,赵亚,等.狼疮性肾炎发病机制研究进展[J].临床医学进展,2023,13(10):15233-15240. MI X, YANG X J, ZHAO Y, et al. Advancements in the pathogenesis of lupus nephritis[J]. Advances in Clinical Medicine,2023,13(10):15233-15240.
[5] LI J C, ZOU Y X, KANTAPAN J, et al. TGF-β/Smad signaling in chronic kidney disease: exploring post-translational regulatory perspectives (review) [J]. Molecular Medicine Reports,2024,30(2):143.
[6] GAO Y F, YANG H, WANG Y H, et al. Evaluation of the inhibitory effect of tacrolimus combined with myco-phenolate mofetil on mesangial cell proliferation based on the cell cycle[J]. International Journal of Molecular Medicine,2020,46(4):1582-1592.
[7] 林梦姣,季晓丽,陈玮.TRAF3在免疫应答中的研究进展[J].中国免疫学杂志,2020,36(1):119-125. LIN M J, JI X L, CHEN W. Research progress of TRAF3 in immune response[J]. Chinese Journal of Im-munology,2020,36(1):119-125.
[8] 陈金淑,陈丕厚,宋依瑾,等.肿瘤坏死因子受体相关因子3调控STING/IFN-I信号通路改善狼疮肾炎足细胞损伤的机制研究[J].临床肾脏病杂志,2023,23(11):932-940. CHEN J S, CHEN P H, SONG Y J, et al. Tumor ne-crosis factor receptor associated factor 3 regulated the signaling pathway of STING/IFN-I for improving the lupus nephritis related podocyte injury and understand-ing its mechanism[J]. Journal of Clinical Nephrolo-gy,2023,23(11):932-940.
[9] STEVENS P E, LEVIN A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline[J]. Annals of Internal Medi-cine,2013,158(11):825-830.
[10] 曾彩虹,刘志红.ISN/RPS狼疮性肾炎病变定义及分型修订共识[J].肾脏病与透析肾移植杂志,2019,28(1):47-51. ZENG C H, LIU Z H. Revision of 2018 international society of nephrology/ ranal pathology society classi-fication for lupus nephritis[J]. Chinese Journal of Ne-phrology, Dialysis & Transplantation,2019,28(1):47-51.
[11] 中华医学会风湿病学分会,国家皮肤与免疫疾病临床医学研究中心,中国系统性红斑狼疮研究协作组.2020中国系统性红斑狼疮诊疗指南[J].中华内科杂志,2020,59(3):172-185. Chinese Rheumatology Association, National Clinical Research Center for Dermatologic and Immunologic Diseases, Chinese Systemic Lupus Erythematosus Treatment and Research Group. 2020 Chinese guide-lines for the diagnosis and treatment of systemic lupus erythematosus[J]. Chinese Journal of Internal Medi-cine,2020,59(3):172-185.
[12] 张福,韩碧翠,刘贞妮.狼疮性肾炎患者血清补体C9，凝溶胶蛋白与肾功能及疾病转归的关系[J].国际检验医学杂志,2024,45(9):1106-1109,1115. ZHANG F, HAN B C, LIU Z N. Relationship be-tween serum complement C9, gelsolin and renal function, disease outcome in patients with lupus ne-phritis[J]. International Journal of Laboratory Medi-cine,2024,45(9):1106-1109,1115.
[13] 杨文卓,王欣,陈崴,等.生物制剂在狼疮肾炎治疗中的应用[J].中华肾脏病杂志,2023,39(7):552-558. YANG W Z, WANG X, CHEN W, et al. Biologics in treatment of lupus nephritis[J]. Chinese Journal of Ne-phrology,2023,39(7):552-558.
[14] 李宛星,周晓霜,李荣山.狼疮肾炎治疗新进展[J].临床肾脏病杂志,2022,22(8): 696-700. LI W X, ZHOU X S, LI R S. Recent advances in the treatment of lupus nephritis[J]. Journal of Clinical Ne-phrology,2022,22(8): 696-700.
[15] LICHTNEKERT J, ANDERS H J, LECH M. Lupus ne-phritis:current perspectives and moving forward[J].Journal of Inflammation Research,2022,12(15):6533-6552.
[16] YANG S, YANG G Y, WANG X Y, et al. SIRT2 al-leviated renal fibrosis by deacetylating SMAD2 and SMAD3 in renal tubular epithelial cells[J]. Cell Death& Disease,2023,14(9):646.
[17] KUNDU S, GHOSH A, YADAV K S, et al. Imperatorin ameliorates kidney injury in diabetic mice by regulating the TGF-β/Smad2/3 signaling axis, epithelial-to-mes-enchymal transition, and renal inflammation[J]. Euro-pean Journal of Pharmacology,2024,963:176250.
[18] RAM C, GAIROLA S, SYED A M, et al. Biochanin A alleviates unilateral ureteral obstruction-induced renal interstitial fibrosis and inflammation by inhibiting the TGF-β1/Smad2/3 and NF-kB/NLRP3 signaling axis in mice[J]. Life Sciences,2022,298:120527.
[19] 张洁,徐璐瑶,吴昱升,等.miR-155靶向SMAD2在小鼠狼疮肾炎足细胞损伤和炎性反应中的影响[J].海南医学院学报,2024,30(5):321-328. ZHANG J, XU L Y, WU Y S, et al. The effect of miR-155 targeting SMAD2 in podocyte injury and inflam-matory response in mouse lupus nephritis[J]. Journal of Hainan Medical University,2024,30(5):321-328.
[20] WU S, JI L N, FAN X M, et al. Jieduquyuzishen pre-scription attenuates renal fibrosis in MRL/lpr mice via inhibiting EMT and TGF-β1/Smad2/3 pathway[J]. Evidence-Based Complementary and Alternative Medi-cine,2022,2022:4987323.
[21] RAYEGO-MATEOS S, MORGADO-PASCUAL J L, VALDIVIELSO J M, et al. TRAF3 modulation: novel mechanism for the anti-inflammatory effects of the vi-tamin d receptor agonist paricalcitol in renal disease[J]. Journal of the American Society of Nephrology, 2020,31(9):2026-2042.
[22] LIANG G Q, TANG H, NI D L, et al. Zishenwan decreases kidney damage in recurrent urinary tract in-fection through the inhibition of toll-like receptor 4 sig-nal[J]. Evidence-Based Complementary and Alternative Medicine, 2018,2018:5968657.
[23] SUN X Q, LIU W S, ZHANG H M, et al. TRAF3 plays a role in lupus nephritis by regulating Th17 cell and Treg cell balance as well as NF-κB signaling pathway in mice[J]. General Physiology and Biophys-ics,2022,41(2):151-158.
[24] 田贵青,李贞琼.狼疮肾炎靶向B细胞治疗研究新进展[J].临床肾脏病杂志,2024,24(4):319-323. TIAN G Q, LI Z Q. Research advances in targeted ther-apy of lupus nephritis[J]. Journal of Clinical Nephrolo-gy,2024,24(4):319-323.
[25] CHEN Z G, KRINSKY A, WOOLAVER R A, et al. TRAF3 acts as a checkpoint of b cell receptor signaling to control antibody class switch recombination and an-ergy[J]. Journal of Immunology,2020,205(3):830-841.
[26] 符妹丽,江强,周仕群,等.系统性红斑狼疮患者尿液Gal-3BP, VSIG4 表达水平与疾病活动度及肾损伤的相关性研究[J].现代检验医学杂志,2024,39(4):88-92,115. FU M L, JIANG Q, ZHOU S Q, et al. Study on the cor-relation among urine Gal-3BP, VSIG4 expression lev-els, disease activity and kidney injury in patients with systemic lupus erythematosus[J]. Journal of Modern Laboratory Medicine,2024,39(4):88-92,115.

相似文献/References:

[1]陈江秀,莫世松,韩　珠,等.狼疮性肾炎患者尿 IL-17，NGAL 及 HMGB1 水平变化及其临床意义[J].现代检验医学杂志,2021,36(03):68.[doi:10.3969/j.issn.1671-7414.2021.03.015]
　CHEN Jiang-xiu,MO Shi-song,HAN Zhu,et al.Changes and Clinical Significance of Urinary IL-17, NGAL andHMGB1 Levels in Lupus Nephritis[J].Journal of Modern Laboratory Medicine,2021,36(05):68.[doi:10.3969/j.issn.1671-7414.2021.03.015]
[2]肖广智,高 旋,丁 进.血清补体C3, C4 水平正常的活动性狼疮性肾炎患者的临床特征与实验室相关指标分析[J].现代检验医学杂志,2022,37(05):39.[doi:10.3969/j.issn.1671-7414.2022.05.009]
　XIAO Guang-zhi,GAO Xuan,DING Jin.Analysis of Clinical and Laboratory Characteristics of the Patients of Active Lupus Nephritis with Normal Levels of Serum Complement C3 and C4[J].Journal of Modern Laboratory Medicine,2022,37(05):39.[doi:10.3969/j.issn.1671-7414.2022.05.009]
[3]高颖颖,李文冬,温 洁,等.狼疮性肾炎患者血清TRIM27 和FOXO1 表达水平及其与自身免疫抗体和疾病活动的相关性分析[J].现代检验医学杂志,2023,38(01):73.[doi:10.3969/j.issn.1671-7414.2023.01.014]
　GAO Ying-ying,LI Wen-dong,WEN Jie,et al.Expression of TRIM27 and FOXO1 in Serum of Patients with Lupus Nephritis and Their Correlation with Autoimmune Antibodies and Disease Activity[J].Journal of Modern Laboratory Medicine,2023,38(05):73.[doi:10.3969/j.issn.1671-7414.2023.01.014]

备注/Memo

备注/Memo:
作者简介：刘瑜瑜（1990-），女，本科，主治医师，研究方向：肾内科，E-mail：liuyuyu19904@163.com。
通讯作者：思雅芳（1989-），女，硕士研究生，主治医师，研究方向：肾病内科，E-mail：1198565256@qq.com。
更新日期/Last Update: 2025-09-15